Voya Investment Management LLC Has $7.34 Million Stake in Twist Bioscience Co. (NASDAQ:TWST)

Voya Investment Management LLC reduced its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,992 shares of the company's stock after selling 7,096 shares during the period. Voya Investment Management LLC owned approximately 0.26% of Twist Bioscience worth $7,342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TWST. Marshall Wace LLP raised its position in shares of Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after acquiring an additional 532,040 shares during the last quarter. Jennison Associates LLC lifted its position in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after acquiring an additional 302,884 shares during the period. American Century Companies Inc. increased its holdings in shares of Twist Bioscience by 63.5% in the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after purchasing an additional 293,751 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after purchasing an additional 237,772 shares during the last quarter.

Twist Bioscience Price Performance

Shares of TWST traded up $1.53 during trading hours on Friday, reaching $39.24. 1,459,508 shares of the company traded hands, compared to its average volume of 980,950. Twist Bioscience Co. has a fifty-two week low of $33.16 and a fifty-two week high of $60.90. The stock has a market capitalization of $2.34 billion, a PE ratio of -11.61 and a beta of 2.34. The stock has a fifty day simple moving average of $39.24 and a 200 day simple moving average of $44.07. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same period in the previous year, the company posted ($0.75) earnings per share. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. As a group, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity

In related news, CEO Emily M. Leproust sold 5,200 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 806 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now directly owns 112,221 shares of the company's stock, valued at $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,432 shares of company stock worth $1,038,170. 3.01% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TWST. Barclays reduced their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Guggenheim set a $50.00 price objective on Twist Bioscience in a report on Friday, March 28th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Finally, Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $52.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.